Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future.

Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Abstract Text:

Robert G Maki,

Objective. In the era of oral molecular kinase inhibitors, cytotoxic chemotherapy agents are somewhat overlooked, but remain the backbone of treatment for most cancers. Patients with non-gastrointestinal stromal tumor sarcomas, such as leiomyosarcoma, liposarcoma, and undifferentiated high-grade pleomorphic sarcoma (formerly called malignant fibrous histiocytoma), have received doxorubicin and ifosfamide as the backbone of their treatment for over 15 years or more. The goal of this article is to review the data that have led to the use of gemcitabine and docetaxel as a useful combination for patients with metastatic sarcomas, and to comment on possible synergy of the combination. Methods and results. The literature regarding the use of gemcitabine, docetaxel, or both, is reviewed, with emphasis on patients with metastatic sarcoma. Results. Activity of gemcitabine and docetaxel is observed in leiomyosarcoma and undifferentiated high-grade pleomorphic sarcoma. There is apparent schedule dependence of the combination in other cancers; it is unclear if schedule matters in patients with sarcomas. The dose and schedule of gemcitabine and docetaxel examined in phase II studies are probably too high for routine practice. Conclusions. The combination of gemcitabine and docetaxel is an effective option for patients with metastatic sarcoma, increasing the armamentarium for the practicing oncologist in treating this heterogeneous group of diseases. Given the low response rate to docetaxel as a single agent, it is likely that there is true clinical synergy of the combination. Disclosure of potential conflicts of interest is found at the end of this article.

Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Publishing Authors By Initials

RG Maki,

For similar organic chemicals: hydrocarbons: hydrocarbons, cyclic: hydrocarbons, alicyclic: cycloparaffins: cyclodecanes: taxoids research abstracts see: organic chemicals: hydrocarbons: hydrocarbons, cyclic: hydrocarbons, alicyclic: cycloparaffins: cyclodecanes: taxoids research

PUBMED ID PMID:

MEDLINE DATE:

Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Journal Published:

PUBLICATION TYPE: Review

Journal: The oncologist

VOLUME: 12

Page Numbers: 999-1006

Journal Abbreviation: Oncologist

ISSN: 1083-7159

DAY: 3

MONTH: Aug

YEAR: 2007

Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Information

Number of References: 44

LANGUAGE: eng

NlmUniqueID: 9607837

Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Keywords Mesh Terms:

KEYWORDS: Taxoids

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Information

Substance Name: Deoxycytidine

Registry Number: 951-77-9

Grant and Affiliation Information for Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future.

AFFILIATION: Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, New York 10021-6007, USA. makir@mskcc.org.

Country: United States

AGENCY: United States NCI

GRANT: P01-CA47179

ACRONYM: CA

MEDLINETA: Oncologist

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future Related Publications

• A novel homogeneous bioluminescence resonance energy transfer element for biomolecular detection with CCD camera or CMOS device.
• A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas.
• An in vitro comparison of bacterial leakage of three common restorative materials used as an intracoronal barrier.
• Brox, a novel farnesylated Bro1 domain-containing protein that associates with charged multivesicular body protein 4 (CHMP4).
• Calphobindins (placental annexins) inhibit protein kinase C.
• Can jua be a weapon in combating oral diseases?
• Characterization of recombinant mouse epidermal-type transglutaminase (TGase 3): regulation of its activity by proteolysis and guanine nucleotides.
• Cohort study of the pathogenesis and molecular epidemiology of catheter-related bloodstream infection in neonates with peripherally inserted central venous catheters *.
• Development of a Multi-channel, Portable Optical Topography System.
• Effects of bisphosphonate on the mandible of rats in the growing phase with steroid-induced osteoporosis.
• Four types of calpastatin isoforms with distinct amino-terminal sequences are specified by alternative first exons and differentially expressed in mouse tissues.
• Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future.
• Isolation and characterization of an anticoagulant protein from human placenta.
• Manipulation of small-molecule inhibitory kinetics modulates MCH-R1 function.
• Measuring balance in the elderly: validation of an instrument.
• Nanowire-transistor based ultra-sensitive DNA methylation detection.
• P53 and p73 differ in their ability to inhibit glucocorticoid receptor (GR) transcriptional activity.
• Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity : a retrospective analysis.
• Recent advances in therapy for gastrointestinal stromal tumors.
• Requirement of different subdomains of calpastatin for calpain inhibition and for binding to calmodulin-like domains.
• Reversible CT changes in uremic encephalopathy.
• Sex difference in cognitive response to antipsychotic treatment in first episode schizophrenia.
• Small cauda equina neurinoma detected by MR imaging.
• Structure and expression of cDNA for calphobindin II, a human placental coagulation inhibitor.
• Structure and properties of calphobindin II, an anticoagulant protein from human placenta.
• THE EFFECTS OF VENTILATION ON THE ABSORPTION AND ELIMINATION OF INHALATION ANAESTHETICS.
• The complete amino acid sequence of rice bran trypsin inhibitor.
• The dnaE173 mutator mutation confers on the alpha subunit of Escherichia coli DNA polymerase III a capacity for highly processive DNA synthesis and stable binding to primer/template DNA.
• The penta-EF-hand protein ALG-2 interacts with a region containing PxY repeats in Alix/AIP1, which is required for the subcellular punctate distribution of the amino-terminal truncation form of Alix/AIP1.
• Transition from a chain-collapse process to a chain-aggregation process of poly(methyl methacrylate) in a mixed solvent.